Watch ALLR. Know when insiders buy.
One email the day a filing lands. Free.
ALLR
Allarity Therapeutics, Inc.
1.42
−0.01 −0.70%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
84
PASS · shorts 84
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $22.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$12.3MNET CASH $14.3M52W 0.81 – 1.88SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$2.7M | −$3.4M | — | -0.21 | −$2.6M | $0 | −$2.6M | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$2.7M | −$2.8M | — | -0.17 | −$4.5M | $64K | −$4.6M | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.9M | −$3.4M | — | -0.21 | −$3.2M | — | — | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$2.5M | −$2.8M | — | -0.19 | −$3.4M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$4.1M | −$2.3M | — | -0.15 | −$5.5M | $0 | −$5.5M | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$3M | −$2.7M | — | -0.25 | −$2.7M | $0 | −$2.7M | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$7.3M | −$7.5M | — | 9.68 | −$3.2M | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$12.3M | −$11.6M | — | -7.71 | −$5.4M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$3.4M | −$1.6M | — | -0.11 | −$7.3M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$4.2M | −$3.8M | — | -22.14 | −$1.4M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$4.9M | −$1.7M | — | 8.58 | −$1.7M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$4.4M | −$4.4M | — | -2.03 | −$5.4M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$12.6M | −$11.2M | — | -0.78 | −$14.8M | $8K | −$14.8M | $3.2M | — |
| FY2024 · to Dec 31 | — | — | −$27.2M | −$24.5M | — | -15.65 | −$17.4M | $298K | −$17.6M | $0 | — |
| FY2023 · to Dec 31 | — | — | −$17.1M | −$11.9M | — | -10.26 | −$12.7M | $0 | −$12.7M | — | — |
| FY2022 · to Dec 31 | — | — | −$34.5M | −$16.1M | — | -3093.42 | −$16.8M | $18K | −$16.8M | — | — |
| FY2021 · to Dec 31 | — | — | −$26.6M | −$26.6M | — | -4.19 | −$14.9M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$8.3M | −$6.6M | — | -2.03 | −$7.3M | $3K | −$7.3M | — | — |
Every number comes from Allarity Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.